Paediatrics

Top Medical News
Shorter antibiotic regimen just as effective for febrile urinary tract infection in children
Yesterday
A 5-day course of oral amoxicillin-clavulanate performs just as wells as a 10-day course in the treatment of febrile urinary tract infection (fUTI) in children, a study has shown.
Maternal T1D a risk factor for congenital heart defects in offspring
5 days ago
Babies born to mothers with type 1 diabetes (T1D) are at increased risk of congenital heart defects, as shown in a study.
Green spaces boost bone health in kids
6 days ago
Children with higher exposure to residential green spaces appear to have greater bone mineral density and a lower risk of having low bone density, as reported in a study.
Food insecurity leads to behavioural problems in children
Jairia Dela Cruz, 6 days ago
Household food insecurity appears to be associated with the manifestation of externalizing and internalizing behaviour problems in young children in Singapore through both nutritional deficits and family stress, according to a study.
Biosensors detect aggression risk in young psychiatric inpatients with autism
Jairia Dela Cruz, 07 Jan 2024
Wearable biosensors and machine learning algorithms show promise in predicting impending aggressive behaviour in youths with autism who are undergoing psychiatric treatment, offering opportunities for intervention and prevention.
Higher folic acid levels during pregnancy may help prevent Kawasaki disease in newborns
07 Jan 2024
Having greater serum folic acid levels and taking folic acid supplements more than once a week during the second and third trimesters appear to lower the risk of Kawasaki disease among infants, according to a study.
Lovo-cel gene therapy shows near-complete VOE resolution in sickle cell disease
Elaine Soliven, 04 Jan 2024

A single infusion of lovotibeglogene autotemcel (lovo-cel) resulted in near-complete resolution of vaso-occlusive events (VOEs) among patients with sickle cell disease (SCD), according to the combined analysis of phase I/II HGB-206 group C and phase III HGB-210 studies presented at ASH 2023.

Special Reports
Product Highlight - Oncaspar
14 Sep 2023
Pegaspargase powder for solution for injection/infusion 3,750 units
Product Highlight - Stelara
09 Jun 2023
Ustekinumab solution for injection (pre-filled syringe) 45 mg/0.5 mL and 90 mg/mL, and concentrate for solution for infusion (vial) 130 mg
Expert insights on current aHUS diagnosis and management strategies
Dr. Elaine Au, Dr. Matthew Lee, Dr. Crystal Lam, Dr. Stella Chim, 19 Apr 2023
Atypical haemolytic uraemic syndrome (aHUS) is a group of rare complement dysregulation disorders characterized by haemolytic anaemia, thrombocytopenia and acute kidney injury in both paediatric and adult patients. Prompt management is crucial to avoid life-threatening complications and invasive interventions. However, early detection and treatment remain challenging because aHUS is primarily diagnosed by exclusion. In an interview with MIMS Doctor, experts from Hong Kong shared current practices in the diagnosis and treatment of aHUS as well as their experience with using the complement component 5 (C5) inhibitor, eculizumab, for these patients.
Updates on juvenile idiopathic arthritis: Classification and treatment strategy
Dr. Nicolino Ruperto, 21 Feb 2023
As the most common type of chronic arthritis in children, juvenile idiopathic arthritis (JIA) can lead to long-term disability and requires precise management based on the particular JIA category. At a recent industry-sponsored webinar, Dr Nicolino Ruperto, paediatrician at the IRCCS Istituto Giannina Gaslini and senior scientist of the Paediatric Rheumatology International Trials Organisation (PRINTO, www.printo.it), Genova, Italy, shared updates in classification and management of JIA, including the latest clinical evidence from the phase III clinical trial of secukinumab, an anti–interleukin (IL)-17A.
Product Highlight - DUPIXENT
02 Dec 2022
Dupilumab solution for injection (pre-filled syringe) 200 mg/1.14 mL and 300 mg/2 mL
Product Highlight - Dupixent
14 Jun 2022
Dupilumab solution for injection (pre-filled syringe) 200 mg/1.14 mL and 300 mg/2 mL
Conference Reports
Experts share essential updates on COVID-19 vaccines
Elvira Manzano, 20 Nov 2023
SARS-CoV-2 continues to evolve into newer variants. Post-Delta, these variants are generally more highly transmissible and immune-evasive, although not more virulent, said Dr Gregory Poland, Mary Lowell Leary Emeritus Professor of Medicine and director of Mayo Vaccine Research Group, Mayo Clinic in Rochester, Minnesota, US, at IDWeek 2023.
Podcast: Professor Flor Munoz discusses the importance of vaccination for pregnant women and children against COVID-19 at IDW
30 Oct 2023
Podcast: Professor Flor Munoz discusses the importance of vaccination for pregnant women and children against COVID-19 at IDWeek 2023
Ritonavir-boosted nirmatrelvir protects older adults against post-COVID conditions
Jairia Dela Cruz, 26 Oct 2023
Treatment with nirmatrelvir/ritonavir helps lower the incidence of post-COVID conditions (PCC) in older adults, according to a large study.
Ceftazidime-avibactam safe, effective in babies with bacterial infections
Stephen Padilla, 20 Oct 2023
Treatment with single or multiple doses of ceftazidime-avibactam (CAZ-AVI) results in favourable clinical outcomes and is well tolerated in hospitalized neonates and young infants with suspected or confirmed bacterial infections, according to a phase IIa study presented at IDWeek 2023.
Bivalent mRNA vaccine confers protection against SARS-COV-2 infection in young children
Elaine Soliven, 18 Oct 2023

Bivalent COVID-19 vaccine conferred protection against SARS-COV-2 infection among children and adolescents aged 5–11 years, according to a recent study presented at IDWeek 2023.

Adverse neurodevelopmental outcomes higher in complicated twins
Audrey Abella, 20 Jul 2023
Survivors of complicated monochorionic diamniotic (MCDA) twin pregnancies (ie, complicated twins) have a higher rate of adverse neurodevelopmental outcomes compared with uncomplicated twins, suggests a study presented at RCOG 2023.
Another IBAT inhibitor makes its case in large PFIC trial
Jairia Dela Cruz, 30 Jun 2023
The ileal bile acid transporter (IBAT) inhibitor maralixibat appears to quell itching and reduce serum bile acid concentration in children with progressive familial intrahepatic cholestasis (PFIC), while having a tolerable safety profile, according to data from the phase III MARCH-PFIC trial said to be the largest to date.